Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia

Brain Res. 2005 Oct 5;1058(1-2):120-8. doi: 10.1016/j.brainres.2005.07.076. Epub 2005 Sep 8.

Abstract

Granulocyte colony-stimulating factor (G-CSF) is a neuroprotective agent and activates endothelial proliferation and bone marrow stem cell mobilization. We studied the effect of G-CSF on angiogenesis and neurological recovery after focal cerebral ischemia. After the induction of transient focal ischemia in rats, G-CSF (50 micro/day, i.p.) or PBS was administered for 3 days. We evaluated the functional recovery, infarct volume, inflammatory infiltration, blood-brain barrier (BBB) disruption, hemispheric atrophy, protein expressions of endothelial nitric oxide synthase (eNOS) and angiopoietins, and the therapeutic time window of G-CSF administration. We then analyzed endothelial cell proliferation, the vascular surface area, the number of branch points, and the vascular length. G-CSF treatment improved behavioral recovery and reduced the infarct volume, the inflammatory infiltration, the BBB disruption, and the hemispheric atrophy. G-CSF injection, starting at 2 h, 1 day, or 4 days after ischemia, resulted in a better functional recovery and a greater reduction in hemispheric atrophy than injection starting at day 7. The vascular surface area, the vascular branch points, the vascular length, the number of BrdU(+) endothelial cells, and eNOS/angiopoietin-2 expression were significantly increased in the G-CSF group compared with the ischemia-only group. G-CSF injection starting at 1 day induced larger endothelial proliferation compared with injection starting at 7 days. In this study, we provide evidences that G-CSF enhances the angiogenesis and reduces the ischemic damage, which promotes the long-term functional recovery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiopoietin-1 / analogs & derivatives
  • Angiopoietin-1 / metabolism
  • Animals
  • Atrophy / drug therapy
  • Atrophy / pathology
  • Atrophy / physiopathology
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / physiology
  • Brain / blood supply
  • Brain / drug effects*
  • Brain / physiopathology
  • Brain Infarction / drug therapy
  • Brain Infarction / pathology
  • Brain Infarction / physiopathology
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Brain Ischemia / physiopathology
  • Cell Proliferation / drug effects
  • Cerebral Arteries / drug effects*
  • Cerebral Arteries / physiology
  • Drug Administration Schedule
  • Encephalitis / etiology
  • Encephalitis / pathology
  • Encephalitis / physiopathology
  • Endothelial Cells / drug effects
  • Endothelial Cells / physiology
  • Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology*
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Male
  • Neovascularization, Physiologic / drug effects*
  • Neovascularization, Physiologic / physiology
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Nitric Oxide Synthase Type III / drug effects
  • Nitric Oxide Synthase Type III / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Recovery of Function / drug effects
  • Recovery of Function / physiology
  • Treatment Outcome

Substances

  • Angiopoietin-1
  • Angpt1 protein, rat
  • Neuroprotective Agents
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Nitric Oxide Synthase Type III